ECSP11011557A - Mimético de smac - Google Patents

Mimético de smac

Info

Publication number
ECSP11011557A
ECSP11011557A ECSP11011557A ECSP11011557A EC SP11011557 A ECSP11011557 A EC SP11011557A EC SP11011557 A ECSP11011557 A EC SP11011557A EC SP11011557 A ECSP11011557 A EC SP11011557A
Authority
EC
Ecuador
Prior art keywords
smac mimetic
smac
mimetic
methods
pharmaceutical compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen M Condon
Yijun Deng
Matthew G Laporte
Original Assignee
Tetralogic Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43411387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011557(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tetralogic Pharm Corp filed Critical Tetralogic Pharm Corp
Publication of ECSP11011557A publication Critical patent/ECSP11011557A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un mimético de SMAC y composiciones farmacéuticas del mismo y métodos de uso.
ECSP11011557 2009-07-02 2011-12-27 Mimético de smac ECSP11011557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22266809P 2009-07-02 2009-07-02
US12/819,221 US8283372B2 (en) 2009-07-02 2010-06-20 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Publications (1)

Publication Number Publication Date
ECSP11011557A true ECSP11011557A (es) 2012-06-29

Family

ID=43411387

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP11011557 ECSP11011557A (es) 2009-07-02 2011-12-27 Mimético de smac

Country Status (26)

Country Link
US (10) US8283372B2 (es)
EP (1) EP2448923B8 (es)
JP (1) JP5674780B2 (es)
KR (1) KR101755218B1 (es)
CN (1) CN102471275B (es)
AP (1) AP3619A (es)
AR (1) AR077629A1 (es)
AU (1) AU2010266525C1 (es)
BR (1) BRPI1013958B1 (es)
CA (1) CA2766162C (es)
CL (1) CL2011003333A1 (es)
CO (1) CO6480975A2 (es)
DK (1) DK2448923T3 (es)
EA (1) EA022061B1 (es)
EC (1) ECSP11011557A (es)
ES (1) ES2565337T3 (es)
HU (1) HUE026982T2 (es)
IL (1) IL217237A (es)
MX (1) MX2011013819A (es)
MY (1) MY153116A (es)
NZ (1) NZ597051A (es)
PE (1) PE20131173A1 (es)
SG (1) SG177404A1 (es)
TW (1) TWI485148B (es)
WO (1) WO2011002684A1 (es)
ZA (1) ZA201109342B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020060A2 (en) * 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
DK1851200T3 (da) * 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
NZ597579A (en) 2009-07-02 2013-06-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
EP2760446A1 (en) 2011-09-30 2014-08-06 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US20130196927A1 (en) * 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
JP2015524441A (ja) * 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション 併用療法
MX381320B (es) 2013-06-25 2025-03-12 Walter & Eliza Hall Inst Medical Res Usos de antagonistas de iap en infecciones intracelulares.
WO2015017520A1 (en) * 2013-07-30 2015-02-05 Tetralogic Pharmaceuticals Corp. Method of treatment
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
IL291844B2 (en) * 2016-02-24 2023-10-01 Childrens Hospital Of Eastern Ontario Res Institute Inc Smc combination therapy for the treatment of cancer
CN109071508B (zh) * 2016-04-27 2021-09-03 南京明德新药研发股份有限公司 作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物
WO2019080928A1 (zh) * 2017-10-27 2019-05-02 南京明德新药研发股份有限公司 一种iap拮抗剂的晶型及其制备方法
AU2018358134A1 (en) * 2017-11-01 2020-05-14 The Regents Of The University Of California Novel agents targeting inhibitor of apoptosis proteins
US10944377B2 (en) * 2017-12-31 2021-03-09 Skyworks Solutions, Inc. Broadband power splitter
WO2019154053A1 (zh) * 2018-02-09 2019-08-15 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
CN112778398A (zh) * 2019-11-07 2021-05-11 杜心赟 肝靶向药、其药物组合物及其用途
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
EP4262763A4 (en) * 2020-12-17 2024-11-20 Council of Scientific & Industrial Research SMAC MIMETICS FOR THE TREATMENT OF CANCER, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION
WO2023194547A1 (en) 2022-04-08 2023-10-12 Medivir Ab Birinapant polymorph h
CA3254393A1 (en) 2022-05-23 2023-11-30 Inhibrx Biosciences, Inc. DR5 AGONIST AND IAP ANTAGONIST POLYTHERAPY
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
EP0049898B2 (en) 1980-10-15 1991-08-14 Takeda Chemical Industries, Ltd. Method for immunochemical assay and kit therefor
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4525300A (en) 1983-01-07 1985-06-25 Japanese Foundation For Cancer Research Human leukemia virus-related peptides, antibodies of the peptides and a process for production of the antibodies
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5208007A (en) 1988-11-22 1993-05-04 Board Of Regents Of The University Of Oklahoma Isotopic tracer composition and method for making and using same
US5023077A (en) 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US5545719A (en) 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
US5766572A (en) 1992-08-05 1998-06-16 Meito Sangyo Kabushiki Kaisha Water-soluble carboxypolysaccharide-magnetic iron oxide complex having a small particle diameter
US5358934A (en) 1992-12-11 1994-10-25 The United States Of America As Represented By The Secretary Of Agriculture Materials and methods for control of pests
US5468494A (en) 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5527775A (en) 1994-10-13 1996-06-18 Enzon, Inc. Reduction of mammalian neoplasms with phospholipase A2 activating substances
US6187557B1 (en) 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
US5786173A (en) 1996-03-19 1998-07-28 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US5977311A (en) 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU2001286730A1 (en) 2000-08-24 2002-03-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
AU2001293189A1 (en) 2000-09-29 2002-04-08 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
US7718600B2 (en) 2000-09-29 2010-05-18 The Trustees Of Princeton University IAP binding compounds
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
US20020160975A1 (en) 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
JP2004531731A (ja) 2001-05-31 2004-10-14 ザ トラスティーズ オブ プリンストン ユニバーシテイ Ｉａｐ結合ペプチドおよびｉａｐに結合する化合物を同定するアッセイ
AU2002323368B2 (en) 2001-08-23 2006-12-07 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
CA2467892A1 (en) 2001-11-21 2003-06-05 The Burnham Institute Methods and compositions for derepression of iap-inhibited caspase
US20060258581A1 (en) 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
CN100384819C (zh) 2002-07-02 2008-04-30 诺瓦提斯公司 与细胞凋亡蛋白抑制剂结合的smac蛋白的肽抑制剂
US7149755B2 (en) 2002-07-29 2006-12-12 Hewlett-Packard Development Company, Lp. Presenting a collection of media objects
US20080199439A1 (en) 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
MXPA06008095A (es) 2004-01-16 2007-03-28 Univ Michigan Mimeticos de smac conformacionalmente restringidos y sus usos.
CA2553871A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
EP1713542A2 (en) 2004-02-05 2006-10-25 Novartis AG COMBINATION OF (a) A DNA TOPOISOMERASE INHIBITOR AND (b) AN IAP INHIBITOR
AU2005218555B2 (en) 2004-03-01 2008-01-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
CA2558615C (en) 2004-03-23 2013-10-29 Genentech, Inc. Azabicyclo-octane inhibitors of iap
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
CA2570321C (en) 2004-07-02 2013-10-08 Genentech, Inc. Inhibitors of iap
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
BRPI0513310A (pt) 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
WO2006020060A2 (en) 2004-07-15 2006-02-23 Tetralogic Pharmaceuticals Corporation Iap binding compounds
JP2008016458A (ja) 2004-08-18 2008-01-24 Teijin Ltd 電磁波吸収シート材料
KR20120127754A (ko) 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
US20060228352A1 (en) * 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
CN101128425B (zh) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Iap二聚体抑制剂
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
US7763604B2 (en) 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2006128455A2 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
MX2007015419A (es) 2005-06-08 2008-02-21 Novartis Ag Compuestos organicos.
US20070203749A1 (en) 2005-08-09 2007-08-30 Sri Chunduru Business methods for compounds for treatment of proliferative disorders
JP2009509128A (ja) 2005-08-09 2009-03-05 テトラロジック ファーマシューティカルズ コーポレーション 増殖性疾患の治療
RU2418807C2 (ru) 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
RU2451025C2 (ru) 2005-12-19 2012-05-20 Дженентек, Инк. Ингибиторы iap
EP2606933A3 (en) 2005-12-20 2014-10-15 Novartis AG Combination of an IAP-inhibitor and a taxane
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
EP1996184A4 (en) 2006-03-21 2010-09-22 Joyant Pharmaceuticals Inc SMALL MOLECULAR APOPTOSIS PROMOTERS
HRP20141253T1 (en) 2006-05-05 2015-03-13 The Regents Of The Universitiy Of Michigan Intermediates for the preparation of bivalent smac mimetics
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
WO2008014229A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CL2007002167A1 (es) * 2006-07-24 2009-01-23 Tetralogic Pharm Corp Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
US20100056495A1 (en) 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110218A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
RU2009118487A (ru) 2006-10-19 2010-11-27 Новартис АГ (CH) Органические соединения
RU2466131C2 (ru) 2006-12-19 2012-11-10 Дженентек, Инк. Имидазопиридиновые ингибиторы iap
WO2008128121A1 (en) 2007-04-12 2008-10-23 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
NZ598890A (en) 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
CA2686638A1 (en) 2007-05-07 2008-11-13 Tetralogic Pharmaceuticals Corp. Tnf.alpha. gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
EP2242362A4 (en) 2008-01-24 2012-04-11 Tetralogic Pharm Corp IAP INHIBITORS
AU2009293403A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. IAP inhibitors
US20120015352A1 (en) 2009-01-29 2012-01-19 Otto-Von-Guericke-Universitat Magdeburg Method of determining sensitivity of human or non-human animal cells to an iap antagonist
NZ596669A (en) 2009-05-28 2013-11-29 Tetralogic Pharm Corp Iap inhibitors
CA2763638A1 (en) 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2760446A1 (en) 2011-09-30 2014-08-06 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US20130196927A1 (en) 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
JP2015524441A (ja) 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション 併用療法
WO2014121178A1 (en) 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Smac mimetic method of treatment
US20140303090A1 (en) 2013-04-08 2014-10-09 Tetralogic Pharmaceuticals Corporation Smac Mimetic Therapy

Also Published As

Publication number Publication date
BRPI1013958A2 (pt) 2019-09-03
TWI485148B (zh) 2015-05-21
ZA201109342B (en) 2014-05-28
IL217237A (en) 2014-09-30
US8986993B2 (en) 2015-03-24
AU2010266525C1 (en) 2015-10-01
NZ597051A (en) 2013-10-25
US20150158908A1 (en) 2015-06-11
US8603816B2 (en) 2013-12-10
AP2012006066A0 (en) 2012-02-29
PE20131173A1 (es) 2013-10-03
IL217237A0 (en) 2012-02-29
US11351221B2 (en) 2022-06-07
DK2448923T3 (en) 2016-02-29
US20170182116A1 (en) 2017-06-29
US20180303897A1 (en) 2018-10-25
KR101755218B1 (ko) 2017-07-07
CN102471275B (zh) 2014-05-28
US20110003877A1 (en) 2011-01-06
US20200282002A1 (en) 2020-09-10
TW201113276A (en) 2011-04-16
AU2010266525A1 (en) 2012-01-19
EA022061B1 (ru) 2015-10-30
CL2011003333A1 (es) 2012-07-20
CA2766162A1 (en) 2011-01-06
KR20120047905A (ko) 2012-05-14
EA201171494A1 (ru) 2012-06-29
EP2448923A1 (en) 2012-05-09
US8283372B2 (en) 2012-10-09
US10034912B2 (en) 2018-07-31
CO6480975A2 (es) 2012-07-16
CN102471275A (zh) 2012-05-23
WO2011002684A1 (en) 2011-01-06
US20230149500A1 (en) 2023-05-18
HK1169410A1 (zh) 2013-01-25
JP5674780B2 (ja) 2015-02-25
HK1171022A1 (en) 2013-03-15
US10596220B2 (en) 2020-03-24
AU2010266525B2 (en) 2015-05-21
EP2448923A4 (en) 2013-05-01
EP2448923B8 (en) 2016-01-27
SG177404A1 (en) 2012-02-28
US20140073579A1 (en) 2014-03-13
BRPI1013958B1 (pt) 2022-04-05
CA2766162C (en) 2018-07-24
AR077629A1 (es) 2011-09-14
US10314881B2 (en) 2019-06-11
AP3619A (en) 2016-02-29
EP2448923B1 (en) 2015-11-25
MY153116A (en) 2014-12-31
HUE026982T2 (en) 2016-08-29
US11951147B2 (en) 2024-04-09
JP2012532129A (ja) 2012-12-13
ES2565337T3 (es) 2016-04-04
US20120115922A1 (en) 2012-05-10
US20130012564A1 (en) 2013-01-10
US20190255139A1 (en) 2019-08-22
MX2011013819A (es) 2012-06-08

Similar Documents

Publication Publication Date Title
MY153116A (en) Smac mimetic
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
BRPI1014316A2 (pt) composição, e, uso de uma composição
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
DOP2012000188A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de empleo
FR2943680B1 (fr) Composition de caoutchoux et pneumatique utilisant cette composition.
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BR112013003536A2 (pt) composição, e utilização de uma composição.
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
BRPI1005431A2 (pt) unidade de carpete, disposição de iluminação e uso da unidade de carpete
BRPI1006953A2 (pt) composição farmacêutica, e, uso de uma composição
BRPI1015091A2 (pt) novo uso
BRPI1011036A2 (pt) uso
SMT201600277B (it) Formulazione peptidica oftalmica topica
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
CL2009001973S1 (es) Mostrador.
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BRPI1010003A2 (pt) uso de uma mistura, e, composição
DK2389166T3 (da) Farmaceutisk sammensætning omfattende aleglitazar
BR112013015090A2 (pt) composição lubrificante, e, uso de uma composição lubrificante
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI1009090A2 (pt) composto, pró-droga, medicamento, métodos, e, uso do composto
UY34613A (es) Composición de limpieza